AstraZeneca Signs Deal to Tackle Japan's Drug Lag (Japan)
This article was originally published in PharmAsia News
Pharmaceutical giant AstraZeneca announced Sept. 26 it had entered a partnership with Tokyo's prestigious Keio University School of Medicine. Currently, there is a significant delay between the time drugs debut in Europe and North American and when they are made available to Japanese patients. By partnering with Keio, AstraZeneca hopes to solve this problem by increasing the number of early clinical trials conducted in Japan. (Click here for more
You may also be interested in...
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.